Genomics Research AI: Governing Access to Genetic Data

Genomics teams are under pressure to use AI for literature review, cohort summarization, variant analysis notes, and collaborator-facing research summaries. The challenge is that genetic data is not just another sensitive text field. It is often re-identifiable, tightly regulated, and mixed with clinical context that can cross HIPAA and GDPR boundaries at the same time. Keeptrusts does not pretend to be a genomics-specific variant interpretation engine, but it does provide a useful governance boundary around text prompts and routed model calls through rbac, data-routing-policy, pii-detector, hipaa-phi-detector, and audit-logger.

Use this page when

• You are using AI in genomics, translational research, or research-adjacent clinical informatics workflows.
• You need to keep raw subject identifiers and sensitive research metadata off non-compliant providers.
• You want to govern access to AI routes without claiming the gateway semantically validates genomic science.

Primary audience

• Primary: Technical Leaders
• Secondary: Technical Engineers, Research governance reviewers

The problem

Genomics AI work usually fails at the boundary between scientific ambition and operational discipline. Researchers want help with summarizing study cohorts, drafting collaborator updates, or turning structured findings into narrative explanations. But the prompt that reaches the model may include subject IDs, sample IDs, phenotypic notes, family history, dates, locations, or clinical text copied from another system. Once that happens, the route is not merely a productivity tool. It is now part of the organization's data-governance perimeter.

There is an additional complication: genetic data is highly specific even when some direct identifiers are removed. That means governance cannot rely only on a "strip the name and move on" mindset. For many genomics workflows, the safest design is to keep raw identifiers tokenized, limit AI access to explicit research roles, and route only to local-only or tightly constrained targets.

Keeptrusts helps with those parts, but it is important to describe the boundary correctly. The gateway can inspect and redact text, evaluate headers and role metadata, and filter providers based on declared data handling attributes. It does not parse VCF semantics, validate scientific claims about variants, or certify that de-identification is complete for every genomics dataset. Those responsibilities remain with the research program. The gateway's job is to reduce exposure and make route decisions reviewable.

That is still valuable because access governance is where many research AI programs break down. A broad literature route becomes a shortcut for internal datasets. An external collaborator gets the same route as an internal bioinformatician. A provider with ordinary cloud defaults is used for prompts that should never leave local infrastructure. Without a formal route policy, those decisions happen informally and inconsistently.

The solution

For genomics research, the best pattern is to make access and routing the primary controls and treat text redaction as a supporting control.

rbac should define who can send research prompts at different sensitivity levels. That means requiring identity headers, using role-specific tool allowlists where appropriate, and applying minimum-necessary PHI rules so only named research roles can proceed when the request text contains PHI-like content. This is more defensible than relying on shared API tokens or a general-purpose "research" role.

data-routing-policy should then enforce the provider side. If your genomics route requires local-only processing, in-memory handling, no internet egress, and tokenized inputs, make those runtime requirements. Keeptrusts will filter out targets whose declared data_policy metadata does not satisfy them. Missing metadata is treated as non-compliant, which is exactly what you want for sensitive research routes.

pii-detector and hipaa-phi-detector still matter, but as a backstop rather than the entire strategy. pii-detector can redact custom study or sample identifiers through detect_patterns, and hipaa-phi-detector adds coverage for PHI-like text that often appears when research prompts are built from clinical systems. That helps the route fail more safely when a researcher includes more context than intended.

The related healthcare pages remain useful reference material because they frame the same underlying controls: Healthcare (HIPAA), Healthcare (EU GDPR), HIPAA PHI Detector, Healthcare Compliance, and Secure Healthcare AI. For genomics, the main extension is to recognize that access governance and local routing often matter even more than output shaping.

Implementation

This example limits a genomics research route to local-only processing, tokenizes custom identifiers, and records the route as audited.

pack:
  name: genomics-research-governance
  version: 1.0.0
  enabled: true

providers:
  targets:
    - id: local-genomics-ai
      provider: ollama
      model: llama3.1:70b
      base_url: http://localhost:11434
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0
        in_memory_only: true
        sanitized: true
        accepts_tokenized_input: true
        allow_internet_egress: false
        local_only_processing: true

policies:
  chain:
    - rbac
    - data-routing-policy
    - pii-detector
    - hipaa-phi-detector
    - audit-logger

policy:
  rbac:
    deny_if_missing:
      - X-Org-ID
      - X-User-ID
      - X-User-Role
    roles:
      bioinformatician:
        allowed_tools:
          - search
          - summarize
          - report_variant_review
      external-collaborator:
        allowed_tools:
          - summarize
    data_access:
      bioinformatician:
        max_sensitivity: restricted
      external-collaborator:
        max_sensitivity: confidential
    minimum_necessary:
      enabled: true
      allowed_phi_roles:
        - bioinformatician
        - principal-investigator

  data-routing-policy:
    require_zero_data_retention: true
    require_in_memory_only: true
    sanitize_before_provider: true
    tokenize_sensitive_fields: true
    allow_internet_egress: false
    local_only_processing: true
    on_no_compliant_provider: block
    log_provider_selection: true

  pii-detector:
    action: redact
    healthcare_mode: true
    detect_patterns:
      - 'SAMPLE-[A-Z0-9]{8}'
      - 'SUBJECT-[0-9]{6}'
    redaction:
      marker_format: label
      include_metadata: true
      custom_markers:
        generic_id: "[GENETIC-IDENTIFIER-REDACTED]"

  hipaa-phi-detector:
    action: redact
    mode: hipaa_18
    safe_harbor_method: true

  audit-logger: {}

The important thing to notice is what this route does not promise. It does not claim the model can safely reason over any raw genomic dataset. It keeps the AI boundary narrow: governed roles, tokenized identifiers, local-only or equivalent provider guarantees, and a decision trail that can be reviewed later.

That is often the correct first step for research programs. Start by constraining the route to literature summaries, de-identified cohort narratives, and internal research drafting where the organization can defend the data path. If a later workflow requires patient-facing interpretation or medical guidance, that should move to a separate route with additional controls like Healthcare Compliance or Human Oversight.

The basic validation loop is short:

kt policy lint --file ./genomics-research-governance.yaml
kt gateway run --policy-config ./genomics-research-governance.yaml --port 41002
kt events tail --policy rbac
kt events tail --policy data-routing-policy

That validates the two most important questions for this route.

1. Did the right role reach the route?
2. Did the route stay on a compliant target set?

If you need a broader review set for a research committee, export recent events and compare them with approved route ownership and provider declarations.

Results and impact

The immediate benefit is that genomics teams stop treating AI access as an informal lab convenience. The route becomes a governed service with named roles, explicit provider constraints, and redaction backstops. That is a much stronger posture for genetic data than relying on ad hoc guidance about what researchers should or should not paste.

This also makes collaboration cleaner. Internal bioinformaticians, external collaborators, and principal investigators can be given different route privileges instead of sharing one access pattern. That reduces the chance that the broadest access path becomes the default path for everyone.

From a governance perspective, the route creates a reviewable record of how genetic-data-adjacent prompts were handled. That matters because genomics programs often face questions from multiple angles at once: research governance, privacy, clinical informatics, and regional data protection. A route with explicit access and routing rules is easier to defend than a workflow built on shared tools and good intentions.

Key takeaways

• Keeptrusts can govern access to genomics AI routes even though it is not a genomics-specific scientific validator.
• For genetic-data-adjacent workflows, access control and provider routing should be the primary controls.
• Use pii-detector custom regexes to tokenize sample and subject identifiers before model calls.
• Use local-only and in-memory requirements in data-routing-policy when external routing is not acceptable.
• Split research drafting routes from patient-facing or clinically interpretive routes instead of trying to make one route do both.

Next steps

• Healthcare (HIPAA)
• Healthcare (EU GDPR)
• HIPAA PHI Detector
• Healthcare Compliance
• Secure Healthcare AI
• RBAC
• Data Routing Policy